Acacia Pharma is a hospital pharmaceutical group focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients. The Group has identified important and commercially attractive unmet needs in nausea & vomiting and has discovered two product candidates based on the same active ingredient, amisulpride, to meet those needs.
The Group’s lead project, BARHEMSYS® for post-operative nausea & vomiting (PONV), has generated positive results in four Phase 3 clinical studies and an NDA has been accepted for filing by the US FDA for marketing approval, with a target review date of 26 February 2020. Its sister project, APD403 for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma has retained rights to commercialise its product candidates in all territories and plans to sell them directly in the US through its own commercial operations. Acacia Pharma intends to establish licensing and/or distribution agreements with selected pharmaceutical partners outside the US.
The Group’s pipeline has been generated by repurposing drugs already marketed for other uses that have biological properties appropriate for their development as patented products for surgical and cancer patients.
Acacia Pharma’s management team has extensive experience in the discovery, development and commercialisation of hospital pharmaceutical products and in drug repurposing.
Acacia Pharma is listed on the Euronext Brussels exchange under the under ISIN code GB00BYWF9Y76 and ticker symbol ACPH.